{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:35:21Z","timestamp":1792978521058,"version":"4.5.0"},"reference-count":140,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NHGRI T32","award":["5T32HG009495"],"award-info":[{"award-number":["5T32HG009495"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Extramedullary multiple myeloma (EMM), defined in this review as soft tissue plasmacytomas resulting from hematogenous spread, is characterized by the ability of MM cells to proliferate outside of the bone marrow microenvironment. It is aggressive, often associated with high-risk cytogenetics and early relapse, and independently portends significantly shorter progression-free and overall survival, even in the era of highly effective immunotherapies. The molecular and microenvironmental factors underlying extramedullary MM dissemination continue to be studied to inform the development of better treatments. In this review, we discuss our current understanding of the biology of EMM, focusing on its distinct molecular and microenvironmental characteristics vis-\u00e0-vis MM. We also review the current treatment strategies, acknowledging the paucity of large, randomized studies specific to this population.<\/jats:p>","DOI":"10.3390\/curroncol32030182","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:59:54Z","timestamp":1742457594000},"page":"182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Extramedullary Multiple Myeloma: Challenges and Opportunities"],"prefix":"10.3390","volume":"32","author":[{"given":"Matthew","family":"Ho","sequence":"first","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0194","authenticated-orcid":false,"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Minehart","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Nabar","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Han","family":"Noll","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luo","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Garfall","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barwick, B.G., Gupta, V.A., Vertino, P.M., and Boise, L.H. (2019). Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01121"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Moser-Katz, T., Joseph, N.S., Dhodapkar, M.V., Lee, K.P., and Boise, L.H. (2021). Game of Bones: How Myeloma Manipulates Its Microenvironment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.625199"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: From bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: Consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Kyle","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1039\/C5CP06547J","article-title":"Challenging compounds for calculating molecular second hyperpolarizabilities: The triplet state of the trimethylenemethane diradical and two derivatives","volume":"18","author":"Champagne","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Kyle","year":"2013","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3324\/haematol.2013.092254","article-title":"Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France","volume":"99","author":"Labopin","year":"2014","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5588\/pha.16.0118","article-title":"Pre-treatment loss to follow-up among smear-positive TB patients in tertiary hospitals, Quetta, Pakistan","volume":"7","author":"Wali","year":"2017","journal-title":"Public Health Action"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Banerjee, R., Cicero, K.I., Lee, S.S., and Cowan, A.J. (2023). Definers and drivers of functional high-risk multiple myeloma: Insights from genomic, transcriptomic, and immune profiling. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1240966"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel","volume":"11","author":"Caers","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","first-page":"890","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","article-title":"Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution","volume":"12","author":"Cibeira","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","article-title":"Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4110\/in.2017.17.4.250","article-title":"Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma","volume":"17","author":"Batsukh","year":"2017","journal-title":"Immune Netw."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/bmt.2017.165","article-title":"Multiple myeloma with extramedullary disease: Impact of autologous stem cell transplantation on outcome","volume":"52","author":"Kumar","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","article-title":"The possible role of burden of therapy on the risk of myeloma extramedullary spread","volume":"96","author":"Mangiacavalli","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-016-0040-7","article-title":"A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial","volume":"5","author":"Ichinohe","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","article-title":"Features of extramedullary disease of multiple myeloma: High frequency of p53 deletion and poor survival: A retrospective single-center study of 834 cases","volume":"15","author":"Deng","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.13383","article-title":"Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation","volume":"169","author":"Weinstock","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.13382","article-title":"Development of extramedullary myeloma in the era of novel agents: No evidence of increased risk with lenalidomide-bortezomib combinations","volume":"169","author":"Varga","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","article-title":"Features of extramedullary myeloma relapse: High proliferation, minimal marrow involvement, adverse cytogenetics: A retrospective single-center study of 24 cases","volume":"91","author":"Rasche","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2404085","article-title":"Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients","volume":"20","author":"Sureda","year":"2006","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2023-181029","article-title":"Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group","volume":"142","author":"Katodritou","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.1067","article-title":"Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma","volume":"67","author":"Oshima","year":"2001","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood.2022018243","article-title":"An unusual case of a multiple myeloma with thyroid involvement at primary diagnosis","volume":"141","author":"Liss","year":"2023","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"NP114","DOI":"10.1177\/0145561319861379","article-title":"Myeloma of Laryngeal Cartilage: Literature Review and Case Study","volume":"100","author":"You","year":"2021","journal-title":"Ear Nose Throat J."},{"key":"ref_38","first-page":"101713","article-title":"A case of Multiple Myeloma with lung plasmacytoma","volume":"39","author":"Saidi","year":"2022","journal-title":"Respir. Med. Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2002.20.1.344","article-title":"Extramedullary sites of involvement in hematologic malignancies: Case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma","volume":"20","author":"Chim","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10428190400011583","article-title":"Extramedullary myeloma representing as a pericardial effusion with tamponade: Two case reports and a further review of 19 cases in the literature","volume":"46","author":"Abelman","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e16567","DOI":"10.1097\/MD.0000000000016567","article-title":"Multiple myeloma with onset of pancreas involvement: A case report","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100971","DOI":"10.1016\/j.eucr.2019.100971","article-title":"Multiple myeloma with testicular involvement: A case report","volume":"26","author":"Yamashita","year":"2019","journal-title":"Urol. Case Rep."},{"key":"ref_43","first-page":"2948","article-title":"Multiple myeloma with rupture of ovarian plasmacytoma","volume":"125","author":"Zhong","year":"2012","journal-title":"Chin. Med. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/archderm.139.4.475","article-title":"Cutaneous Involvement in Multiple Myeloma: A Clinicopathologic, Immunohistochemical, and Cytogenetic Study of 8 Cases","volume":"139","author":"Requena","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4103\/jcrt.jcrt_156_22","article-title":"Multiple muscle involvement in relapsed multiple myeloma: A rare case","volume":"18","author":"Erdemir","year":"2022","journal-title":"J. Cancer Res. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mathew, J., Lubitz, S., and Zaidan, J. (2020). SUN-928 Adrenal Plasmacytoma in Multiple Myeloma Patient-An Unusual Presentation. J. Endocr. Soc., 4.","DOI":"10.1210\/jendso\/bvaa046.455"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood.2024025250","article-title":"Development of hyperdiploidy starts at an early age and takes a decade to complete","volume":"145","author":"Samur","year":"2024","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/s41375-020-01051-x","article-title":"Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz, A., Rodr\u00edguez-Garc\u00eda, Y., Encinas, J., Maroto-Mart\u00edn, E., Castellano, E., Teixid\u00f3, J., and Mart\u00ednez-L\u00f3pez, J. (2021). The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers, 13.","DOI":"10.3390\/cancers13020217"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/stem.3174","article-title":"CXCR4 expression in the bone marrow microenvironment is required for hematopoietic stem and progenitor cell maintenance and early hematopoietic regeneration after myeloablation","volume":"38","author":"Singh","year":"2020","journal-title":"Stem Cells"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.exphem.2006.06.017","article-title":"Chemokines in multiple myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4161\/cam.18975","article-title":"Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells","volume":"6","author":"Sahin","year":"2012","journal-title":"Cell Adhes. Migr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0609.2008.01087.x","article-title":"Clinicopathological features of extramedullary recurrence\/relapse of multiple myeloma","volume":"81","author":"Cerny","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2141.2005.05493.x","article-title":"The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system","volume":"129","author":"Chang","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","article-title":"Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma","volume":"116","author":"Dahl","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","article-title":"Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma","volume":"117","author":"Sahara","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/leu.2009.65","article-title":"Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors","volume":"23","author":"Garayoa","year":"2009","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/s41467-024-47793-5","article-title":"Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes","volume":"15","author":"Binder","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10585-007-9108-4","article-title":"Extravasation and homing mechanisms in multiple myeloma","volume":"25","author":"Vanderkerken","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Garc\u00e9s, J.J., San-Miguel, J., and Paiva, B. (2022). Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora\u2019s Box of Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14061430"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000490231","article-title":"CD56 for Multiple Myeloma: Lack of CD56 May Be Associated with Worse Prognosis","volume":"140","author":"Miyazaki","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"McAvera, R., Quinn, J., Murphy, P., and Glavey, S. (2023). Genetic Abnormalities in Extramedullary Multiple Myeloma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411259"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ejh.12688","article-title":"Cytogenetics in multiple myeloma patients progressing into extramedullary disease","volume":"97","author":"Besse","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2006","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5507\/bp.2015.014","article-title":"Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data","volume":"159","author":"Sevcikova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.12223","article-title":"Cytogenetics of extramedullary manifestations in multiple myeloma","volume":"161","author":"Billecke","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2164449","DOI":"10.1080\/16078454.2022.2164449","article-title":"Identification of long noncoding RNA NEAT1 as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis","volume":"28","author":"Chen","year":"2023","journal-title":"Hematology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.12291","article-title":"Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease","volume":"161","author":"Egan","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kriegova, E., Fillerova, R., Minarik, J., Savara, J., Manakova, J., Petrackova, A., Dihel, M., Balcarkova, J., Krhovska, P., and Pika, T. (2021). Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93835-z"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/PAS.0000000000001459","article-title":"Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma","volume":"44","author":"Liu","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16440","article-title":"The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma","volume":"189","author":"Long","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mithraprabhu, S., Sirdesai, S., Chen, M., Khong, T., and Spencer, A. (2018). Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071858"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Qu, X., Chen, L., Qiu, H., Lu, H., Wu, H., Qiu, H., Liu, P., Guo, R., and Li, J. (2015). Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed. Res. Int., 2015.","DOI":"10.1155\/2015\/787809"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","article-title":"Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion","volume":"26","author":"Ryu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13039-018-0357-5","article-title":"Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse","volume":"11","author":"Smetana","year":"2018","journal-title":"Mol. Cytogenet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/bloodadvances.2022009477","article-title":"Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1097\/CM9.0000000000002351","article-title":"Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13148-018-0597-6","article-title":"Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses","volume":"10","author":"Yao","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: Insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2024-203350","article-title":"The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration","volume":"144","author":"Zanwar","year":"2024","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.2023022295","article-title":"RAS\/RAF landscape in monoclonal plasma cell conditions","volume":"144","author":"Schavgoulidze","year":"2024","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.2024024869","article-title":"RASping myeloma genomics","volume":"144","author":"Paiva","year":"2024","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2022017010","article-title":"Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood-2024-204341","article-title":"Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease","volume":"144","author":"Maclachlan","year":"2024","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2643-3230.BCD-20-0164","article-title":"ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment","volume":"2","author":"Bianchi","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1038\/s41467-018-07497-z","article-title":"ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-\u03b2 signalling","volume":"9","author":"Pinho","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3892\/or.2013.2516","article-title":"The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer","volume":"30","author":"He","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"Kastritis","year":"2009","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Puertas, B., Gonz\u00e1lez-Calle, V., Sobejano-Fuertes, E., Escalante, F., Queiz\u00e1n, J.A., B\u00e1rez, A., Labrador, J., Alonso-Alonso, J.M., Garc\u00eda de Coca, A., and Cantalapiedra, A. (2023). Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15051558"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Yin, J., Zhou, X., Li, X., Yuan, C., Chu, X., Hao, L., Wu, H., and Zhong, Y. (2024). Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-79537-2"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/S2152-2650(24)01666-5","article-title":"MM-336 Long-Term Follow-Up From the Phase 1\/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"24","author":"Garfall","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2023-177749","article-title":"Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease","volume":"142","author":"Pan","year":"2023","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.ijrobp.2024.07.2275","article-title":"Patterns of Failure in Multiple Myeloma with Extramedullary Disease Following Anti-BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy","volume":"120","author":"Nakashima","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2023-190019","article-title":"Efficacy of Bispecific Antibodies Vs CAR-T in the Treatment of Extramedullary Disease and High-Risk Cytogenetics in Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis","volume":"142","author":"Vegivinti","year":"2023","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: A meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Que, Y., Xu, M., Xu, Y., Almeida, V.D.F., Zhu, L., Wang, Z., Wang, Y., Liu, X., Jiang, L., and Wang, D. (2021). Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.755866"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2022-170119","article-title":"Extramedullary Relapse Post CAR-T","volume":"140","author":"Richard","year":"2022","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/S2152-2650(24)01664-1","article-title":"MM-328 Efficacy and Safety of Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1\/2 MajesTEC-1 Study","volume":"24","author":"Costa","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_134","first-page":"308.e301","article-title":"Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Real-World Experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1200\/JCO.2023.41.16_suppl.8058","article-title":"Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database","volume":"41","author":"Jayabalan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): Final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"Minnema","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A phase 2 clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2024-198403","article-title":"Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:57:05Z","timestamp":1760029025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":140,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030182"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030182","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}